Manipal further sweetens offer for Fortis Healthcare

NEW DELHI: The Manipal-TPG combine today revised the offer for Fortis Healthcare by committing to invest in the cash-strapped firm at Rs 180 per share, thus increasing the valuation to Rs 9,403 crore.

In a regulatory filing, Fortis Healthcare Ltd (FHL) said it has received revised offer from Manipal and TPG with a proposal to invest in the company, while making public a letter sent by Manipal Health Enterprises Pvt Ltd (MHEPL) to the Fortis board.

Having lost out to the Munjal-Burmans combine last week, Manipal-TPG which was the first to make a offer to Fortis Healthcare Ltd, said that for purposes of the merger, a value of Rs 9,403 crore shall be attributed to FHL under its revised offer.

On the other hand, a value of Rs 6,070 crore shall be attributed to MHEPL as had been originally determined by the independent valuers of for the purpose of the transaction, it said in the letter.

“The preferential allotment shall be undertaken at a price of Rs 180 per share. For purposes of the merger, a value of Rs 9,403 crore shall be attributed to FHL and a value of Rs 6,070 crore shall be attributed to MHEPL as had been originally determined by the independent valuers of for the purpose of the transaction.

  • Related Posts

    Safdarjung Hospital performs its first dual kidney transplant using organs from marginal donor

    The Indian Air Force airlifted the retrieved organs to Delhi from Command Hospital, Chandimandir, where the 62-year-old donor was declared brain dead. New Delhi: Vardhman Mahavir Medical College (VMMC) and…

    Hospital stocks slide up to 6% after Supreme Court flags drug mark-ups at corporate hospitals

    The court asked the Centre why a 16 per cent retail margin could not apply to all medicines, and will hear the matter again on 12 October. New Delhi: Shares…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    Three arrested after liquor bottles found at pharma firm

    Three arrested after liquor bottles found at pharma firm

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources